NRIX Nurix Therapeutics
- 18.440
- +3.150+20.60%
- 18.250
- -0.190-1.03%
Nurix Therapeutics News
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
Express News | Nurix Therapeutics Shares Are Trading Higher After HC Wainwright & Co. Maintained a Buy Rating and Raised Its Price Target From $19 to $26
Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.BMO Capital
Nurix Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Nurix Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Nurix Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $26 From $19
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $26
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $19 to $26.
Nurix Releases Promising Phase 1 Data on NX-5948 for Chronic Lymphocytic Leukemia
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Sunday, Nurix Therapeutics Inc (NASDAQ:NRIX) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton's tyrosine kinase (BTK).
Express News | JP Morgan Maintains Overweight on Nurix Therapeutics, Raises Price Target to $31
Sector Update: Health Care Stocks Decline Premarket Monday
Health care stocks were declining premarket Monday with the Health Care Select Sector SPDR Fund (XLV) recently 0.3% lower and the iShares Biotechnology ETF (IBB) down 0.5%. Nurix Therapeutics (NRIX) w
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $14 to $35
On Jun 17, major Wall Street analysts update their ratings for $Nurix Therapeutics(NRIX.US)$, with price targets ranging from $14 to $35.Morgan Stanley analyst Terence Flynn maintains with a hold rati
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell
US equity futures were flat premarket Monday as investors searched for fresh cues at the start of a holiday-shortened week. Dow Jones Industrial Average futures were down 0.2%, S&P 500 futures were 0.
Sector Update: Health Care
Health care stocks were declining premarket Monday with the Health Care Select Sector SPDR Fund (XLV) retreating 0.3% and the iShares Biotechnology ETF (IBB) down 0.5%. Nurix Therapeutics (NRIX) share
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose sharply in today's pre-market trading after the company announced results from its ongoing clinical trial of NX-5948 in patients with relapsed ref
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of More Economic Data
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.2% higher as the markets traded mixed in Monday's premarket activ
Top Premarket Gainers
Scinai Immunotherapeutics (SCNI) shares surged 94% Monday premarket, extending Friday's rally. The Aaron's Company (AAN) shares advanced 31% after the company agreed to a takeover offer from IQVenture
Express News | Nurix Therapeutics Shares Are Trading Higher After the Company Announced Results From Its Ongoing Clinical Trial of NX-5948 in Patients With Relapsed Refractory Chronic Lymphocytic Leukemia
Nurix Therapeutics Shares Rise on Positive Leukemia Drug Results
Shares of Nurix Therapeutics jumped after the company reported positive results from a clinical trial of its treatment for relapsed refractory chronic lymphocytic leukemia.
Express News | Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 104.22% Needham $31 → $31 Reiterates Buy → Buy 06/05/2024 130.57% Piper Sandler $35 → $35 Maint
Analysis
Price Target
No Data
